Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (MDT) is a global leader in medical technology, developing innovative healthcare solutions that address chronic diseases and complex conditions. This dedicated news hub provides investors and professionals with timely updates on the company's strategic initiatives, regulatory milestones, and technological breakthroughs.
Access authoritative information spanning earnings announcements, product approvals, partnership developments, and clinical trial outcomes. Our curated collection ensures you stay informed about MDT's advancements in cardiac care, neuromodulation, diabetes management, and surgical robotics.
Discover press releases detailing regulatory submissions, executive appointments, and global market expansions. Each update is verified for accuracy, offering insights into how Medtronic maintains its position at the forefront of medical innovation while navigating evolving healthcare landscapes.
Bookmark this page for direct access to primary source materials and analysis-free reporting on MDT's operational developments. Regular updates ensure you never miss critical information impacting the medical technology sector.
On September 22, 2021, Medtronic (NYSE:MDT) announced that the U.S. Patent Trial and Appeal Board has affirmed all claims in seven patents related to its InterStim™ sacral neuromodulation devices, dismissing challenges from Axonics. The affirmed patents include U.S. Patent Nos. 8,457,758, 8,738,148, and aspects of 9,821,112. Medtronic plans to resume its IP infringement case in California, seeking to protect its proprietary technology. These patents ensure that Medtronic's innovations remain protected as they expire in 2024 and 2025.
Medtronic has initiated the BRAIVE™ IDE study, enrolling its first patient for the Braive™ growth modulation system aimed at treating Adolescent Idiopathic Scoliosis (AIS). Conducted across the U.S., Canada, and the UK, this clinical trial will assess the device's safety and effectiveness. The Braive system aims to correct spinal curvature while allowing continued growth, addressing a significant pediatric need in scoliosis treatment. The study reaffirms Medtronic's commitment to innovation in pediatric spine care, as approximately 4% of children are affected by scoliosis globally.
On September 13, 2021, Medtronic plc (NYSE:MDT) announced it secured three victories in an intellectual property dispute against Axonics. The U.S. Patent and Trademark Office's Patent Trial and Appeal Board upheld Medtronic's patents related to its InterStim™ systems, which are crucial for sacral neuromodulation technology. This follows a previous affirmation of another key patent in September 2020. Medtronic plans to resume its infringement lawsuit against Axonics once the remaining patent reviews are concluded.
Medtronic plc (NYSE: MDT) has launched a pilot program with Mpirik, aimed at addressing disparities in care for sudden cardiac arrest (SCA). This collaboration seeks to identify high-risk patients through Mpirik's AI platform, Cardiac Intelligence®, by screening electronic health records at five hospitals.
The program aims to tackle treatment disparities affecting women and men of color, who receive implantable cardioverter defibrillators (ICDs) at lower rates than white men. Through this initiative, Medtronic aims to enhance patient care and reduce inequalities in treatment.
Medtronic (NYSE:MDT), a leader in medical technology, will participate in several virtual investor conferences. Key events include the Wells Fargo Healthcare Conference on September 9, featuring Bob White at 10:40 am EDT; the Morgan Stanley Global Healthcare Conference on September 14 with Geoff Martha at 10:15 am EDT; and the BofA Global Healthcare Conference on September 17 at 12:35 pm EDT, with Rob ten Hoedt. Live webcasts will be available, with archived recordings later. Medtronic aims to enhance global healthcare solutions.
Medtronic plc (NYSE:MDT) released promising results from the NAVABLATE study, presented at the European Respiratory Society International Congress 2021, demonstrating the safety and efficacy of bronchoscopic microwave ablation for malignant lung nodules. The study involved 30 patients from the UK and Hong Kong, achieving 100% technical success with only a 3.3% adverse event rate. This method offers a new treatment option for patients ineligible for surgery or stereotactic body radiation therapy. The Emprint Ablation Catheter Kit has received Breakthrough Device Designation from the FDA.
BetterInvesting Magazine has designated Medtronic PLC (NYSE: MDT) as its 'Stock to Study' and D.R. Horton Inc. (NYSE: DHI) as its 'Undervalued Stock' for the November 2021 issue. This announcement underscores the importance of self-guided investment education, especially in light of recent Social Security discussions. CEO Ken Zendel emphasizes the need for individuals to take charge of their financial futures. The selections aim to assist investors in making informed decisions. More information can be found through BetterInvesting's online tools.
Medtronic (NYSE: MDT) announced FDA approval for its Evolut™ FX transcatheter aortic valve replacement (TAVR) system on August 24, 2021. This advanced device aims to improve ease-of-use and precision for patients suffering from symptomatic severe aortic stenosis. The Evolut FX system maintains superior hemodynamic performance and offers new features for enhanced visualization during procedures. Plans for limited commercial release in fall 2021 and a full launch in early 2022 highlight its market potential.
Medtronic plc (NYSE: MDT) reported Q1 fiscal 2022 results with revenue of $8.0 billion, a 23% increase year-over-year. GAAP diluted EPS was $0.56, up 56%, while non-GAAP diluted EPS rose 127% to $1.41. U.S. revenue grew 22% to $4.1 billion, comprising 51% of total revenue. The company reiterated its FY22 revenue guidance at approximately 9% growth and raised its EPS forecast by $0.05 to a range of $5.65 to $5.75. Medtronic highlighted significant growth in several divisions, including Surgical Innovations and Cardiovascular, indicating a strong recovery from COVID-19 impacts.
On August 20, 2021, Medtronic plc (NYSE: MDT) announced a cash dividend of $0.63 per ordinary share for Q2 of fiscal year 2022, reflecting a 9% increase from the previous year. This marks the company's 44th consecutive year of dividend increases, solidifying its status as a constituent of the S&P 500 Dividend Aristocrats index. The dividend is set to be paid on October 15, 2021, to shareholders recorded by September 24, 2021.
